World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: Netherlands Trial Register
Last refreshed on: 28 April 2013
Main ID:  NTR3172
Date of registration: 02/12/2011
Primary sponsor: University Medical Center Utrecht (UMCU)
Public title: Detection of recurrent head and neck tumours after chemoradiation with a tumor-sensitive MRI technique.
Scientific title: Detection of recurrent head and neck squamous cell carcinomas with Diffusion Weighted MRI after (chemo)radiation. - RETURNED
Date of first enrolment: 1/12/2011
Target sample size: 75
Recruitment status: recruiting
URL:  http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=3172
Study type:  intervention
Study design:  Randomised: No; Masking: None; Control: Not applicable; Group: Parallel; Type: Single arm  
Countries of recruitment
The Netherlands
Contacts
Name: W.  Grolman
Address:  , Dept. of Otolaryngology Room G05.129 Heidelberglaan 100 3584 CX Utrecht The Netherlands
Telephone: +31 (0)88 75 566 44
Email: W.Grolman@umcutrecht.nl
Affiliation: 
Name: W.  Grolman
Address:  , Dept. of Otolaryngology Room G05.129 Heidelberglaan 100 3584 CX Utrecht The Netherlands
Telephone: +31 (0)88 75 566 44
Email: W.Grolman@umcutrecht.nl
Affiliation: 
Key inclusion & exclusion criteria
Inclusion criteria: 1. Patients with a oropharyngeal, hypopharyngeal, or laryngeal squamous cell carcinoma treated with (chemo)radiation with curative intent;

2. A clinical suspicion of a recurrence;

3. Last radiotherapy: > 2 months and < 3 years ago;

4. ?Informed consent? signed by patient;

5. Age ≥ 18 years.

Exclusion criteria: 1. Patients with contraindication for MRI or contrast agent;

2. Patients who received salvage surgery for the primary lesion;

3. Patients whom recurrence is so obvious that no additional imaging confirmation is necessary for the decision to take biopsies.


Age minimum:
Age maximum:
Gender:
Health Condition(s) or Problem(s) studied
Radiotherapy, Squamous cell carcinoma (SCC), Recurrent

Intervention(s)
One additional Diffusion Weighted MRI added to the regular imaging of choice.
Primary Outcome(s)
The diagnostic performance of DW-MRI for the detection of recurrence in patients with clinical suspicion of recurrent or persistent HNSCC after initial (chemo) radiation will be primarily reflected by the PPV of DW-MRI. Furthermore, the NPV, discrimination, sensitivity and specificity will be assessed.
Secondary Outcome(s)
1. Number of futile biopsies with DW-MRI as selection strategy for endoscopy with taking of biopsies;

2. Discordant pairs (Regular imaging vs. DW-MRI);

3. Number of missed cases by DW-MRI compared to regular imaging;

4. Number of extra cases detected by DW-MRI compared to regular imaging.
Secondary ID(s)
NL37889.041.11
Source(s) of Monetary Support
University Medical Center Utrecht (UMCU)
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history